Cancer Archives

News and Trends 7 Jan 2016

3 French Bioentrepreneurs are Awarded for Being Stubborn

Building a company is extremely difficult and obstination is sometimes needed to reach success. The organisation, France Biotech, has given a price to the founder of Innate-Pharma, OSE Pharma and Effimune for their respective success. Why? From left to right, Hervé Brailly, CEO & Founder of Innate-Pharma, Denis Lucquin, Managing Director of Sofinnova Partners, Maryvonne Hiance, […]

January 7, 2016 - 3 minutesmins - By Philip Hemme

merck msd cancer immunoncology complix alphabody

News and Trends 7 Jan 2016

Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

Complix is a Belgian Immuno-Oncology Biotech with a proprietary Alphabody platform, which has now attracted a €260M strategic drug discovery collaboration with Merck Sharp & Dohme (MSD). Under the terms of the agreement, Complix will use its proprietary Alphabody platform to tackle two intra-cellular cancer targets. One example is the myeloid leukemia cell-1 protein (MCL-1), […]

January 7, 2016 - 2 minutesmins - By Dani Bancroft

porridge vomit emesis acacia trial baremsis

News and Trends 5 Jan 2016

Say Goodbye to Post-Operation Nausea with this Phase III UK Trial Success

An anti-vomiting medication for post-operative patients has smashed its phase III trial in the UK in one of the largest ever post-operation-nausea studies…ever. Roll on FDA approval. Acacia Pharma is a Cambridge based clinical-stage biotech which looks to provide supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment. […]

January 5, 2016 - 3 minutesmins - By Dani Bancroft

msd avelumab pdl1 immunooncology pfizer etinostat

News and Trends 5 Jan 2016

How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay…

By targeting platinum resistant Ovarian cancer, Avelumab is a new anti-PD-L1 checkpoint inhibitor on the Cancer block. This just affirms how PD-L1 receptor is seen as the current breakthrough therapeutic target in Immuno-Oncology. Program-Death ligand 1 (PD-L1) is already a common target for mAbs in immuno-oncology. If expressed on the tumor cells, this enables the […]

January 5, 2016 - 3 minutesmins - By Dani Bancroft

In Depth 5 Jan 2016

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

January 5, 2016 - 7 minutesmins - By Jerome Topsent

nanomedicine nanoxray nanobiotix prostatecancer trials

News and Trends 4 Jan 2016

French Nano-Xrays to Kill Prostate Cancer in Phase I/II Trial

A Parisian Nanomedicine biotech is using it’s proprietary NanoXray technology to enhance radiotherapy. Now a candidate to treat Prostate cancer has received FDA approval for a phase I/II trial in the US. Nanobiotix is seeking to develop NBTXR3 for patients with intermediate and high-risk prostate cancer, with the aim of providing effective tumor destruction and […]

January 4, 2016 - 3 minutesmins - By Dani Bancroft

leukemia ucart19 cellectis cancer cart trial UK

News and Trends 4 Jan 2016

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

So it begins…dubbed the ‘Miracle Cure’ for Blood Cancer, UCART19 is now set to begin its journey to Human trials in the UK. Just 2 days before Christmas, the French billion euro Biotech, Cellectis, submitted a clinical trial application to the Medicines & Healthcare products Regulatory Agency (MHRA). Specifically, the request was to approve initiation […]

January 4, 2016 - 2 minutesmins - By Dani Bancroft

aging regenerative medicine genetics genome longevity

News and Trends 4 Jan 2016

Genomics’ Holy Grail: The Secret to Super-Longevity Lies in your Genes

The search for the Holy Grail in aging has long been a focus in regenerative medicine, which poses the question: why do some of us age better than others? Now growing evidence in Genomic Studies shows that there are key genetic players in the Aging game… Ever since the Human Genome Project, which began 25 […]

January 4, 2016 - 4 minutesmins - By Dani Bancroft

astrazeneca acerta pharma acquitision leukemia myeloma oncology cancer1

News and Trends 21 Dec 2015

Mystery Biotech No One has Ever Heard of in Biggest Deal of the Year for $7Bn

Acerta Pharma is an elusive Netherlands based Biotech with pipelines in Blood cancer and solid tumors which has somehow wrangled the biggest Biotech deal of 2015 with Pharma Giant AstraZeneca. Acerta Pharma is a Biotech start-up founded in 2012 which combines two technology platforms in drug discovery and development with a broad target range, from […]

December 21, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 21 Dec 2015

Here’s my Chat with the CBO of Immunocore, the Only EU Biotech to have ever raised €300M in one Round

Last Thursday at Genesis in London, I had the chance to meet with Eva-Lotta Allan, CBO of Immunocore (and previously from Ablynx). After a last-minute confirmation before the event, we came to meet and it helped me understand why Immunocore could be the next Biotech success-story in Europe… I’m sure you’ve heard of Immunocore this year. This […]

December 21, 2015 - 5 minutesmins - By Philip Hemme

hypoxia cancer hpv inthera aglaia oncology

News and Trends 17 Dec 2015

The Assault on Solid Tumors: How ‘Blinding’ Cancer is an Attractive Therapeutic Approach

The Dutch Oncology VC Specialist Aglaia has invested €3.4M in the Swiss Start-Up Inthera Bioscience for their Small molecule platform against solid tumors. Aglaia is a venture capital firm based in Bilthoven (NL) which has 3 funds under their management for specialist investment into Oncology research. Last year they raised over €50M as part of […]

December 17, 2015 - 3 minutesmins - By Dani Bancroft

ovarian cancer gamamabs antibodies bpifrance rothschild

News and Trends 16 Dec 2015

Ovarian Cancer Kills 50,000 Every Year. Now a French Biotech has Bagged €15M to Fight it.

GamaMabs from France (Paris & Toulouse) has secured a €15M Series B Fundraising round for its Antibody targeting Gynecological cancers. GamaMabs Pharma is a French biotechnology company developing innovative monoclonal antibodies in cancer. GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 (formerly known as 3C23K), and they have previously partnered with Curie Cancer Institute […]

December 16, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

3 French Bioentrepreneurs are Awarded for Being Stubborn

Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

Say Goodbye to Post-Operation Nausea with this Phase III UK Trial Success

How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay…

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

French Nano-Xrays to Kill Prostate Cancer in Phase I/II Trial

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

Genomics’ Holy Grail: The Secret to Super-Longevity Lies in your Genes

Mystery Biotech No One has Ever Heard of in Biggest Deal of the Year for $7Bn

Here’s my Chat with the CBO of Immunocore, the Only EU Biotech to have ever raised €300M in one Round

The Assault on Solid Tumors: How ‘Blinding’ Cancer is an Attractive Therapeutic Approach

Ovarian Cancer Kills 50,000 Every Year. Now a French Biotech has Bagged €15M to Fight it.

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!